Lina Life Insurance "80% of the 2030 Generation Choose Targeted Cancer Treatment Rider"

Lina Life Insurance announced on the 21st that 80% of the subscribers to the special contract covering targeted cancer treatment are in their 20s and 30s.

[Asia Economy Reporter Oh Hyung-gil] LINA Life Insurance announced on the 21st that younger age groups have shown higher subscription rates to the special rider covering targeted anticancer treatment.

In December last year, LINA Life became the first in the industry to launch the 'Targeted Anticancer Drug Approval Treatment Rider,' which exclusively covers high-cost targeted treatments and obtained a six-month exclusive usage right. This rider also covers third-generation immuno-oncology drugs, which became a social issue beyond the medical field after winning the Nobel Prize in Physiology or Medicine in 2018.

The company stated that an analysis of cancer insurance subscribers up to March showed a high rider attachment rate among younger age groups.

For those under 20, the rate exceeded 90%, and for those in their 20s and 30s, it recorded 80%. The higher rider attachment rate among younger subscribers is attributed to the characteristics of targeted anticancer treatment.

Choi Chang-hwan, head of the TM Product Team at LINA Life, explained, "Targeted treatment can increase survival and cure rates and has significantly fewer side effects, allowing patients to maintain daily and work life even during anticancer treatment. The fact that over 80% of subscribers in their 20s and 30s add this rider reflects the younger working population’s greater awareness of the need to prepare for targeted anticancer treatment to prevent income loss."

Jo Ji-eun, Vice President of LINA Life, said, "We place greater significance on developing products that customers discover and choose first. We will continuously innovate our products so that when customers think of cancer insurance, LINA Life is their first consideration."

This content was produced with the assistance of AI translation services.